Jeff Ambroso is a board-certified toxicologist with 23 years of experience in nonclinical safety evaluation of drugs and biotechnology products, in both public and private sectors.
Jeff has served as the preclinical safety representative on multiple project teams developing drugs for a variety of indications at all stages of drug development. He has been a study director or study monitor on a wide variety of toxicology studies including general, safety pharmacology, reproductive, genetic, and carcinogenicity studies, including specialized investigative studies. He has authored nonclinical safety sections of regulatory submissions and had successful interactions with global regulatory agencies.
At RTI International, Jeff has worked closely with both the TB Alliance and CARB-X to develop novel therapies to treat bacterial pathogens and is familiar with several classes of antibacterials which have characteristic toxicity profiles.